Celgene, Cipla Resolve Patent Claims Over Cancer Drug
Cipla Ltd. said Friday it will postpone its launch of a generic form of Celgene Corp.'s brand-name cancer drug Revlimid until after the chemotherapy formula's patents expire, ending litigation accusing the...To view the full article, register now.
Already a subscriber? Click here to view full article